A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T cells and immune checkpoint blockades (ICBs) have made remarkable breakthroughs in cancer treatment, but the efficacy is still limited for solid tumors due to tumor antigen heterogeneity and the tumor immune microenvironment. The restrained treatment efficacy prompted us to seek new potential therapeutic methods.

Methods

In this study, we conducted a small molecule compound library screen in a human BC cell line to identify whether certain drugs contribute to CAR T cell killing. Signaling pathways of tumor cells and T cells affected by the screened drugs were predicted via RNA sequencing. Among them, the antitumor activities of JK184 in combination with CAR T cells or ICBs were evaluated in vitro and in vivo.

Results

We sel

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC9838049 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature